Trial Profile
A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Jan 2021 Data (n=266) pooled from two studies (Study 1017 and ARCHER 1050) were used for longitudinal tumor growth inhibition model to evaluate the effectiveness of the dacomitinib dosing regimen methods, presented at the 2020 World Conference on Lung Cancer.
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 19 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov